EVGN.OQ
Latest Trade
6.08USDChange
0.13(+2.18%)Volume
566,965Today's Range
-
6.9452 Week Range
-
6.94As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 5.95 |
|---|---|
Open | 6.04 |
Volume | 566,965 |
3M AVG Volume | 5.70 |
Today's High | 6.94 |
Today's Low | 6.04 |
52 Week High | 6.94 |
52 Week Low | 0.75 |
Shares Out (MIL) | 36.49 |
Market Cap (MIL) | 696.99 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Evogene Reports Third Quarter 2020 Financial Results
Lavie Bio Announces Positive Results For LAV311 And LAV312 In Its Bio-Fungicide Program
Biomica Initiates Large-Scale Production Of Live Bacterial Product Candidate Consortium
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.
Industry
Biotechnology & Drugs
Contact Info
13 Gad Feinstein st.
Park Rehovot P.O.B 2100
7612002
Israel
+972.8.9311900
http://www.evogene.com/Executive Leadership
Martin S. Gerstel
Chairman of the Board
Ofer Haviv
President, Chief Executive Officer
Alex Taskar
Chief Financial Officer
Ido Dor
Executive Vice President & General Manager Ag-Biologicals
Mark Kapel
Executive Vice President-Technology
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 272.06 |
Price To Book (MRQ) | 3.44 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 5.48 |
LT Debt To Equity (MRQ) | 3.72 |
Return on Investment (TTM) | -43.15 |
Return on Equity (TTM) | -33.89 |
* EVOGENE AND MARRONE BIO INNOVATIONS ANNOUNCE PHASE ADVANCEMENT IN THEIR INSECT CONTROL COLLABORATION
* EVOGENE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
* EVOGENE ANNOUNCES POSITIVE 2ND YEAR FIELD TRIAL RESULTS IN CORN BIO-STIMULANT AG-BIOLOGICALS PROGRAM Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.